<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医学界血液频道 | wechat-feeds</title><link>http://MzUyNDYyNjk1Nw.favicon.privacyhide.com/favicon.ico</link><description>医学界血液频道是领先的血液领域专业媒体，我们传播国内外前沿学术动态，提供有用、有趣、有态度的专业知识，报道领域内发生的新鲜事。投稿或合作，请联系zl@yxj.org.cn</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 15 Jun 2021 21:29:19 +0800</pubDate><image><url>http://MzUyNDYyNjk1Nw.favicon.privacyhide.com/favicon.ico</url><title>医学界血液频道 | wechat-feeds</title><link>http://MzUyNDYyNjk1Nw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>侵袭性淋巴瘤联合疗法，利妥昔单抗成「万金油」？|EHA 2021</title><link>https://mp.weixin.qq.com/s/KGOwVorEFUcZ2ClDcrDn7w</link><description></description><content:encoded><![CDATA[侵袭性淋巴瘤联合疗法，利妥昔单抗成「万金油」？|EHA 2021]]></content:encoded><pubDate>Tue, 15 Jun 2021 19:30:34 +0800</pubDate></item><item><title>Ponatinib治疗模式使CML患者预期寿命与正常人无异！｜EHA2021</title><link>https://mp.weixin.qq.com/s/i_S1b78dGPprzMartqNZ5A</link><description></description><content:encoded><![CDATA[Ponatinib治疗模式使CML患者预期寿命与正常人无异！｜EHA2021]]></content:encoded><pubDate>Tue, 15 Jun 2021 19:30:34 +0800</pubDate></item><item><title>注意，这类人群别再开阿司匹林，严重可致心跳骤停！</title><link>https://mp.weixin.qq.com/s/_wA1vLHCSaDcBjyi8Em1wQ</link><description></description><content:encoded><![CDATA[注意，这类人群别再开阿司匹林，严重可致心跳骤停！]]></content:encoded><pubDate>Tue, 15 Jun 2021 19:30:34 +0800</pubDate></item><item><title>达雷妥尤单抗、Isa-KRd四联、Ixazomib大放异彩！看三大临床试验，共话MM治疗！｜EHA 2021</title><link>https://mp.weixin.qq.com/s/rHSe9H2dN3dDMw6kcbJ3YQ</link><description></description><content:encoded><![CDATA[达雷妥尤单抗、Isa-KRd四联、Ixazomib大放异彩！看三大临床试验，共话MM治疗！｜EHA 2021]]></content:encoded><pubDate>Mon, 14 Jun 2021 20:01:27 +0800</pubDate></item><item><title>对于初诊CLL，伊布替尼联合维奈克拉将擦出怎样的火花？｜血液周刊</title><link>https://mp.weixin.qq.com/s/l_3JtMgGAPaS86v0d06gtw</link><description></description><content:encoded><![CDATA[对于初诊CLL，伊布替尼联合维奈克拉将擦出怎样的火花？｜血液周刊]]></content:encoded><pubDate>Mon, 14 Jun 2021 20:01:27 +0800</pubDate></item><item><title>6分钟带你脑电图入门</title><link>https://mp.weixin.qq.com/s/ICjIPZRYoEnvGI8tHpG5cg</link><description></description><content:encoded><![CDATA[6分钟带你脑电图入门]]></content:encoded><pubDate>Mon, 14 Jun 2021 20:01:27 +0800</pubDate></item><item><title>应对cHL，抗PD-1治疗、CD30靶向药物齐上阵，更有PET影像组学助力预测复发风险！|EHA 2021</title><link>https://mp.weixin.qq.com/s/r5sPALrOgFv1nvjhyxGH7g</link><description></description><content:encoded><![CDATA[应对cHL，抗PD-1治疗、CD30靶向药物齐上阵，更有PET影像组学助力预测复发风险！|EHA 2021]]></content:encoded><pubDate>Sun, 13 Jun 2021 20:21:02 +0800</pubDate></item><item><title>打造重点品牌，构建创新标地！陆道培医院正式签署战略合作，携手实现产业升级！</title><link>https://mp.weixin.qq.com/s/ayD47hAqXZ-VsETU2gWCsA</link><description></description><content:encoded><![CDATA[打造重点品牌，构建创新标地！陆道培医院正式签署战略合作，携手实现产业升级！]]></content:encoded><pubDate>Sun, 13 Jun 2021 20:21:02 +0800</pubDate></item><item><title>反复头晕找不到原因，这个检查可别忘！</title><link>https://mp.weixin.qq.com/s/z9yOwdrNiwVwkYsjgujrEw</link><description></description><content:encoded><![CDATA[反复头晕找不到原因，这个检查可别忘！]]></content:encoded><pubDate>Sun, 13 Jun 2021 20:21:02 +0800</pubDate></item><item><title>ECHELON-1研究：BV联合化疗，或将成为初诊进展期HL的治疗新选择！｜EHA 2021</title><link>https://mp.weixin.qq.com/s/lnh4HQZoql1MG-EM-3iGjg</link><description></description><content:encoded><![CDATA[ECHELON-1研究：BV联合化疗，或将成为初诊进展期HL的治疗新选择！｜EHA 2021]]></content:encoded><pubDate>Sat, 12 Jun 2021 20:57:41 +0800</pubDate></item><item><title>今天，来聊聊组织细胞疾病——LCH和ECD的诊疗！｜ASH学习笔记</title><link>https://mp.weixin.qq.com/s/eJ0U6ztMs7wxY2JvIuWBsw</link><description></description><content:encoded><![CDATA[今天，来聊聊组织细胞疾病——LCH和ECD的诊疗！｜ASH学习笔记]]></content:encoded><pubDate>Sat, 12 Jun 2021 20:57:41 +0800</pubDate></item><item><title>现代心肺复苏全解读</title><link>https://mp.weixin.qq.com/s/aQS8kAVRyh9TZSwNa_qEjw</link><description></description><content:encoded><![CDATA[现代心肺复苏全解读]]></content:encoded><pubDate>Sat, 12 Jun 2021 20:57:41 +0800</pubDate></item><item><title>新一代抗CD20单抗——奥妥珠单抗获批，滤泡性淋巴瘤治疗迈入新时代！</title><link>https://mp.weixin.qq.com/s/mCVAW_Ej3rRH4xfVq0o8Og</link><description></description><content:encoded><![CDATA[新一代抗CD20单抗——奥妥珠单抗获批，滤泡性淋巴瘤治疗迈入新时代！]]></content:encoded><pubDate>Fri, 11 Jun 2021 20:22:52 +0800</pubDate></item><item><title>盘一盘细胞疗法在ALL治疗中的新突破！|EHA 2021</title><link>https://mp.weixin.qq.com/s/1Yxe5gKXOSTheHl9QbnkXA</link><description></description><content:encoded><![CDATA[盘一盘细胞疗法在ALL治疗中的新突破！|EHA 2021]]></content:encoded><pubDate>Fri, 11 Jun 2021 20:22:52 +0800</pubDate></item><item><title>新生儿「Apgar评分」的5大细节，每个妈妈都要知道</title><link>https://mp.weixin.qq.com/s/e2uRatLtBWxE8Am-ZRcdFg</link><description></description><content:encoded><![CDATA[新生儿「Apgar评分」的5大细节，每个妈妈都要知道]]></content:encoded><pubDate>Fri, 11 Jun 2021 20:22:52 +0800</pubDate></item><item><title>R/R AML治疗面面观！看维奈克拉联合治疗大趋势｜EHA 2021</title><link>https://mp.weixin.qq.com/s/GpVYTNjbR3VAfZjP_xwMsA</link><description></description><content:encoded><![CDATA[R/R AML治疗面面观！看维奈克拉联合治疗大趋势｜EHA 2021]]></content:encoded><pubDate>Thu, 10 Jun 2021 22:04:25 +0800</pubDate></item><item><title>关于AA和PNH的治疗新进展，看看这些研究你就知道了！｜EHA 2021</title><link>https://mp.weixin.qq.com/s/gTy6S5mrRZZpnXmYrigLyg</link><description></description><content:encoded><![CDATA[关于AA和PNH的治疗新进展，看看这些研究你就知道了！｜EHA 2021]]></content:encoded><pubDate>Thu, 10 Jun 2021 22:04:25 +0800</pubDate></item><item><title>一文读懂，帕金森治疗药物该如何选择</title><link>https://mp.weixin.qq.com/s/9lt_tVRLDIV0lR-rDw4EYQ</link><description></description><content:encoded><![CDATA[一文读懂，帕金森治疗药物该如何选择]]></content:encoded><pubDate>Thu, 10 Jun 2021 22:04:25 +0800</pubDate></item><item><title>本次大会LBA研究到底花落谁家？精彩内容，等你来看！|EHA 2021</title><link>https://mp.weixin.qq.com/s/QE7vuFq1G-KHw2I-DNdvIw</link><description></description><content:encoded><![CDATA[本次大会LBA研究到底花落谁家？精彩内容，等你来看！|EHA 2021]]></content:encoded><pubDate>Wed, 09 Jun 2021 21:39:01 +0800</pubDate></item><item><title>血液肿瘤“老牌”治疗手段最近有啥新进展？速来打卡！｜EHA 2021</title><link>https://mp.weixin.qq.com/s/4mykO6KDyE7XcwZiQg-n9g</link><description></description><content:encoded><![CDATA[血液肿瘤“老牌”治疗手段最近有啥新进展？速来打卡！｜EHA 2021]]></content:encoded><pubDate>Wed, 09 Jun 2021 21:39:01 +0800</pubDate></item></channel></rss>